Alzheimer's disease (AD) is one of the most common forms of dementia. AD is a chronic
syndrome of the central nervous system that causes a decline in cognitive function and …

Current pharmacotherapy for Alzheimer's disease involves compounds that are aimed at
increasing the levels of acetylcholine in the brain by facilitating cholinergic …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central
nervous system (CNS) which is the most common cause of dementia in the elderly. It is …

In the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters. During
the advancement of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to …

Alzheimer's disease (AD) is well-known as a severe neurodegeneration disease involving
complicated etiologies, and cholinesterase inhibition remain the prevailing mode of clinical …

Background: Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's
disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and …

Alzheimer's disease (AD) is characterized by progressive dementia caused by the loss of the
presynaptic markers of the cholinergic system in the brain areas related to memory and …

Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic
improvement in Alzheimer′ s disease (AD) because cholinergic deficit is a consistent and …

Alzheimer's disease (AD) is the most common age-related neurodegenerative disease and
has become an urgent public health problem in most areas of the world. Substantial …

Alzheimer's disease (AD) is the most common form of neurodegenerative disorders. If more
effective therapies than the ones currently available are not developed that either prevent …